Gastroenterologie up2date, Inhaltsverzeichnis Gastroenterologie up2date 2017; 13(03): 204-206DOI: 10.1055/s-0043-114901 Studienreferate Georg Thieme Verlag KG Stuttgart · New York Kommentar Max Reinshagen Artikel empfehlen Abstract Artikel einzeln kaufen Alle Artikel dieser Rubrik Ein Kommentar zu: Morbus Crohn: signifikant höhere Ansprechraten unter Ustekinumab vs. PlaceboGastroenterologie up2date 2017; 13(03): 204-204DOI: 10.1055/s-0043-114893 Volltext Referenzen Literatur 1 Sands BE, Chen J, Feagan BG. et al. Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohnʼs disease: a phase 2a study. Gastroenterol (epub ahead of print April 5, 2017). 2 Feagan BG, Sandborn WJ, DʼHaens G. et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohnʼs disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet (epub ahead of print April 17, 2017).
